grant
Therapeutic drug monitoring for linezolid in the treatment of rifampin-resistant tuberculosis: a pragmatic randomized controlled trial
Organization ALBERT EINSTEIN COLLEGE OF MEDICINELocation BRONX, UNITED STATESPosted 1 Dec 2024Deadline 30 Nov 2029
NIHUS FederalResearch GrantFY202621+ years oldAIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAddressAdultAdult HumanAdverse ExperienceAdverse effectsAdverse eventAffectAminoglycosidesAntitubercular AgentsAntitubercular DrugsBindingBlood PlasmaBlood PlateletsBone Marrow SuppressionClinicalClinical TrialsComplexDeath RateDoseDrug KineticsDrug MonitoringDrug Resistance TuberculosisDrug Resistant TBDrug Resistant TuberculosisDrug TargetingDrug resistanceDrug resistance in tuberculosisDrug toxicityDrugsEnrollmentEpidemicExtreme drug resistant tuberculosisExtremely drug resistant tuberculosisGram-Positive Bacterial InfectionsGram-positive infectionsGuidelinesHIVHIV associated syndemicHIV co-occurring epidemicHIV dual epidemicHIV individualsHIV infected individualsHIV infected personsHIV intersecting epidemicsHIV peopleHIV positive individualsHIV positive peopleHIV related syndemicHIV syndemicHIV/MtbHIV/TBHIV/mycobacterium tuberculosisHIV/tuberculosisHematologyHemoglobinHumanHuman Immunodeficiency VirusesIncidenceIndividualInjectableInterruptionLAV-HTLV-IIILinezolidLymphadenopathy-Associated VirusM tbM tuberculosisM tuberculosis infectionM. tbM. tb infectionM. tuberculosisM. tuberculosis infectionM. tuberculosis/HIVM.tb infectionM.tuberculosis infectionMTB infectionMarrow plateletMeasuresMedicationMitochondriaModelingModern ManMolecular InteractionMonitorMulti-Drug ResistanceMultidrug ResistanceMultiple Drug ResistanceMultiple Drug ResistantMycobacterium tuberculosisMycobacterium tuberculosis (MTB) infectionMycobacterium tuberculosis infectionMyelosuppressionNeurologicNeurologicalObservational StudyOralOxazolidinonesPLWHPNS DiseasesPWHParticipantPatientsPeripheral Nerve DiseasesPeripheral Nervous System DiseasesPeripheral Nervous System DisordersPeripheral NeuropathyPharmaceutical PreparationsPharmacokineticsPharmacologyPlasmaPlasma SerumPlateletsPopulationProbabilityRNA, Ribosomal, 16SRandomizedRandomized, Controlled TrialsRecommendationRegimenResearchResistanceResistance developmentResistance to Multi-drugResistance to MultidrugResistance to Multiple DrugResistant developmentResistant to Multiple DrugResistant to multi-drugResistant to multidrugReticuloendothelial System, Serum, PlasmaRibosomal RNARifampicin resistanceRifampicin resistantRifampin resistanceRifampin resistantRiskRisk FactorsRoleSeveritiesSiteSouth AfricaStructureTB drug resistanceTB drugsTB infectionTB resistanceTB therapyTB treatmentTestingTherapeuticTherapeutic IndexTherapeutic UsesThrombocytesTimeToxic effectToxicitiesTreatment EfficacyTreatment FailureTreatment ProtocolsTreatment RegimenTreatment ScheduleTuberculosisTuberculostatic AgentsUpdateVancomycinVirus-HIVVisitXDR-TBXDR-TuberculosisZyvoxadulthoodanti-TBanti-TB drugsanti-microbialanti-tuberculosisanti-tuberculosis drugsantiTBantimicrobialarmbactericidalbactericideclinical riskcompound repositioningcompound repurposingdetermine efficacydeveloping resistancedisseminated TBdisseminated tuberculosisdrug efficacydrug repositioningdrug repurposingdrug resistance in TBdrug resistantdrug resistant in tuberculosisdrug standarddrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationenrollevaluate efficacyexamine efficacyexperienceextensive drug resistanceextensively drug resistantextensively drug resistant TBextensively drug resistant tuberculosisextreme drug resistancehuman immunodeficiency virus syndemicimprovedindividuals infected with HIVindividuals with HIVindividuals with human immunodeficiency virusinfection due to Mycobacterium tuberculosisinter-individual variabilityinter-individual variationintervention efficacymitochondrialmortalitymortality ratemtbmulti-drug resistantmultidrug resistantnew therapeutic uses for existing drugsnew use of drugnew uses for an approved drugnew uses for existing drugsobservational research studyobservational surveyopen labelopen label studypeople infected with HIVpeople infected with human immunodeficiency viruspeople living with HIVpeople with HIVpeople with human immunodeficiency viruspharmacological repurposingprematureprematuritypreventpreventingprogramsprospectiverRNArandomisationrandomizationrandomized control trialrandomized, clinical trialsrandomly assignedrepositioning approved drugsrepositioning existing drugsrepurpose approved drugsrepurpose approved medicationrepurpose approved therapeuticrepurpose existing drugsrepurpose existing medicationrepurpose existing medicinerepurpose existing therapeuticsrepurpose existing therapiesrepurpose medicinerepurposing a drugrepurposing agentrepurposing candidatesrepurposing established drugsrepurposing established medicationrepurposing existing pharmacological agentsrepurposing medicationrepurposing of already existing drugsrepurposing pharmaceuticalsresistance in TBresistance in tuberculosisresistance to Drugresistance to rifampicinresistance to rifampinresistance to therapyresistantresistant TBresistant to Drugresistant to rifampicinresistant to rifampinresistant to therapyresistant tuberculosisresponsescreeningscreeningsside effectsimulationsocial rolestandard of caresuccesstherapeutic efficacytherapeutic repositioningtherapeutic repurposingtherapeutic resistancetherapy efficacytherapy failuretherapy resistanttreat M. tuberculosistreat Mtbtreat Mycobacterium tuberculosistreat tbtreat tuberculosistreatment centertreatment resistancetreatment risktuberculosis drugstuberculosis infectiontuberculosis resistancetuberculosis therapytuberculosis treatmenttuberculous spondyloarthropathy
Description preview
PROJECT SUMMARY
Drug-resistant tuberculosis (TB) is a major global epidemic and poses a particular threat to people living
with HIV. With limited effective drugs available for treatment, multidrug-, and extensively drug-resistant TB
carry a high mortality rate and threaten global TB and HIV control efforts.
New and repurposed medications have…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click